Poly Medicure, also known as Poly Medicure Limited, is a leading player in the medical device industry, headquartered in India. Established in 1998, the company has made significant strides in the healthcare sector, particularly in the fields of infusion therapy, vascular access, and wound care. With a strong operational presence across Asia, Europe, and the Americas, Poly Medicure has positioned itself as a trusted provider of innovative medical solutions. The company’s core offerings include a diverse range of products such as intravenous catheters, blood transfusion sets, and surgical sutures, all designed with a focus on safety and efficacy. Poly Medicure is recognised for its commitment to quality and has achieved several certifications, enhancing its reputation in the global market. With a robust portfolio and a dedication to advancing healthcare, Poly Medicure continues to set benchmarks in the medical device industry.
How does Poly Medicure's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Poly Medicure's score of 23 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2025, Poly Medicure reported total carbon emissions of approximately 33,379,500 kg CO2e, comprising 3,337,950 kg CO2e from Scope 1 emissions and 40,088,730 kg CO2e from Scope 2 emissions. The Scope 1 emissions breakdown includes 249,480 kg CO2e from mobile combustion, 963,290 kg CO2e from fugitive emissions, and 2,125,180 kg CO2e from stationary combustion. For the previous year, 2024, the company recorded total emissions of about 23,198,500 kg CO2e, with Scope 1 emissions at 2,319,850 kg CO2e and Scope 2 emissions at 33,962,280 kg CO2e. Poly Medicure has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or initiatives as part of their climate commitments. The company’s emissions data is not cascaded from any parent organisation, indicating that all reported figures are directly from Poly Medicure Limited. In the context of their operations in India, no emissions data has been reported for 2024 and 2023, suggesting a lack of transparency or data collection in that region. Overall, while Poly Medicure has made strides in reporting their emissions, further commitments and reduction initiatives would enhance their climate strategy.
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Scope 1 | 3,114,940 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 30,230,620 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Poly Medicure is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
